There are limited options for treatment with cytotoxic regimens as prostate cancer is a highly chemoresistant
11) Similarly, activation of the anaplastic lymphoma kinase (ALK) signal transducer and activator of transcription 3 (STAT3) pathway is also able to induce PD-L1 expression in ALK-carrying T-cell lymphoma and chemoresistant
non-small cell lung cancer (NSCLC).
Successful treatment of a chemoresistant
tumor with temozolomide in an adult patient: report of a recurrent intracranial mesenchymal chondrosarcoma.
Previous reports indicate that the ginger component 6-shogaol induces cell death in chemoresistant
hepatoma cells and induce activity against breast cancer.
cancer cells thrive in immunosuppressed environments and travel through the blood with ease to initiate cancer cell metastasis.
Particularly, AB23 showed remarkable activity on the paditaxel-resistant ovarian cancer A2780 cells, indicating that it might be used for treatment of chemoresistant
Accordingly, two therapeutic strategies were currently used in the clinical trials: One was to inhibit the cytoprotective function of autophagy to improve the killing efficacy of chemotherapy drugs or resensitize the chemoresistant
tumor cells to drugs; the other was to induce autophagic cell death in the apoptosis-defective tumor cells, which showed high resistance to apoptosis by activating autophagic pathways.
The selective inhibition of nuclear PKCzeta restores the effectiveness of chemotherapeutic agents in chemoresistant
cells," Cell Cycle, vol.
Besides difficulty in diagnosis, the treatment regimens, duration, drug combinations, drug efficacy assessment, treatment end-points criteria are largely debatable subjects and the probable causes of the recent resurgence of chemoresistant
One of the two non-resistant lines and its resistant clone were deficient in their DNA mismatch repair systems, which results in genetic instability, increased susceptibility to neoplastic transformation, and greater development of chemoresistant
Background: To investigate the role of a topoisomerase I inhibitor (topotecan) in chemoresistant
ovarian cancer-initiating cells.
Several novel agents are now in clinical trials in patients with chemoresistant
breast cancer, including rucaparib, an oral small-molecule inhibitor of PARP (poly ADP-ribose polymerase), for triple-negative breast cancer; palbociclib, an oral and selective inhibitor of cyclin dependent kinases 4 and 6, in women with hormone receptor-positive / HER2-negative disease; and trastuzumab emtansine, a conjugate of trastuzum ab and the cytotoxic agent mertansine, in patients with chemoresistant
HER2-positive breast cancer, Dr.